Aptar Pharma is set to introduce an oro-mucosal spray device in Germany, used to treat multiple sclerosis (MS) patients suffering from muscle spasticity, following the approval.

The mouth spray device is used to deliver Sativex (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) to treat MS patients.

Patients who are administring Sativex by oromucosal spray have a flexible dosing regime which is particularly important to meet the variable nature of both spasticity and multiple sclerosis from patient to patient.

Aptar Pharma has developed mouth spray device in collaboration with GW Pharmaceuticals.